Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Sunday 05.04.2020 at 10:00 AM CEST
Settings

Settings

1. WO1991000092 - INHIBITION OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR PRODUCTION BY MONOCYTES AND/OR MACROPHAGES

Publication Number WO/1991/000092
Publication Date 10.01.1991
International Application No. PCT/US1990/003367
International Filing Date 12.06.1990
Chapter 2 Demand Filed 10.01.1991
IPC
A61K 31/44 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 498/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 513/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
CPC
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 513/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Y02A 50/411
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
38Medical treatment of vector-borne diseases characterised by the agent
408the vector-borne disease being caused by a protozoa
411of the genus Plasmodium, i.e. Malaria
Applicants
  • SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101, US (AllExceptUS)
  • BADGER, Alison, Mary [US/US]; US (UsOnly)
  • BENDER, Paul, Elliot [US/US]; US (UsOnly)
  • ESSER, Klaus, Max [US/US]; US (UsOnly)
  • GRISWOLD, Don, Edgar [US/US]; US (UsOnly)
  • NABIL, Hanna [US/US]; US (UsOnly)
  • LEE, John, C. [US/US]; US (UsOnly)
  • VOTTA, Barholomew, Jude [US/US]; US (UsOnly)
  • SIMON, Philip, Leonard [US/US]; US (UsOnly)
Inventors
  • BADGER, Alison, Mary; US
  • BENDER, Paul, Elliot; US
  • ESSER, Klaus, Max; US
  • GRISWOLD, Don, Edgar; US
  • NABIL, Hanna; US
  • LEE, John, C.; US
  • VOTTA, Barholomew, Jude; US
  • SIMON, Philip, Leonard; US
Agents
  • DINNER, Dara, L. ; Corporate Patents - U.S., N160 SmithKline Beecham Corporation P.O. Box 7929 Philadelphia, PA 19101, US
Priority Data
365,34913.06.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITION OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR PRODUCTION BY MONOCYTES AND/OR MACROPHAGES
(FR) INHIBITION DE LA PRODUCTION D'INTERLEUKINE-1 ET DU FACTEUR DE NECROSE DE TUMEURS PAR L'UTILISATION DE MONOCYTES ET/OU DE MACROPHAGES
Abstract
(EN)
A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such a human an effective, interleukin-1 production inhibiting amount of a diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead atom wherein said second ring may also contain sulfur, oxygen or an additional nitrogen atom, and may contain additional unsaturation. This invention relates to a method of inhibiting the production of Tumor Necrosis Factor (TNF) by monocytes or macrophages in a human in need thereof which comprises administering to such mammal an effective, TNF production inhibiting amount of a compound of formula (I) as described herein. The compounds of formula (II) are generally described as diaryl-substituted imidazole fused to a seond heterocyclic ring containing a nitrogen bridgehead wherein said ring may also contain sulfur, oxygen, or an additional nitrogen atom, and may contain additional unsaturation.
(FR)
Un procédé d'inhibition de la production d'interleukine-1 par des monocytes et/ou des macrophages chez un être humain consiste à administrer à ce dernier une quantité d'inhibition efficace de la production d'interleukine-1 d'un imidazole à substitution diaryl fusionné sur un second anneau hétérocyclique contenant un atome de tête de pont d'azote, ce second anneau pouvant contenir également un atome de soufre, d'oxygène ou d'azote supplémentaire, et pouvant contenir une insaturation additionnelle. Cette invention concerne un procécé d'inhibition de la production du facteur de nécrose de tumeur (TNF) par des monocytes ou des macrophages chez un être humain en ayant besoin, et consiste à administrer à ce mammifère une quantité d'inhibition efficace de production de TNF d'un composé de formule (I) ci-décrite. Les composés de formule (II) sont généralement un imidazole à subsitution diaryl fusionné sur un second anneau hétérocyclique contenant un atome de tête de pont d'azote, cet anneau pouvant contenir également un atome de soufre, d'oxygène ou d'azote supplémentaire, et pouvant contenir une insaturation additionnelle.
Latest bibliographic data on file with the International Bureau